ArticleTheranostics2019
Effective chemoimmunotherapy by co-delivery of doxorubicin and immune adjuvants in biodegradable nanoparticles.
Article in Theranostics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 64 citations in OpenAlex.
- Navigating toxicity in lung cancer immunotherapy: challenges and advances in Nano medicine drug delivery.Journal of the Egyptian National Cancer Institute · 2026Review
- Advanced Human Immune Cell-Organoid Co-Cultures for Functional Testing of Cancer Nanovaccines.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Tumor microenvironment conversion through intelligent nanomedicine: a paradigm shift in overcoming chemoresistance.Frontiers in oncology · 2026Review
- Biodegradable 3D Injectable Amino Acid Hydrogels Delivering Immune Adjuvant for Enhancing Immunotherapy in Colon Cancer.Cancer science · 2025Article
- CCL20 in the tumor microenvironment: implications for cancer progression and therapeutic approaches.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Review
- Nanomaterials-driven in situ vaccination: a novel frontier in tumor immunotherapy.Journal of hematology & oncology · 2025Review
- Chemotherapy-elicited extracellular vesicle CXCL1 from dying cells promotes triple-negative breast cancer metastasis by activating TAM/PD-L1 signaling.Journal of experimental & clinical cancer research : CR · 2024Article
- Multitarget, multiagent PLGA nanoparticles for simultaneous tumor eradication and TME remodeling in a melanoma mouse model.Drug delivery and translational research · 2024Article
- Regulating Tumor-Associated Macrophage Polarization by Cyclodextrin-Modified PLGA Nanoparticles Loaded with R848 for Treating Colon Cancer.International journal of nanomedicine · 2024Article
- Nanoparticle-Mediated Synergistic Chemoimmunotherapy for Cancer Treatment.International journal of nanomedicine · 2024Review
- Multifunctional nanocomposites modulating the tumor microenvironment for enhanced cancer immunotherapy.Bioactive materials · 2024Review
- Reactive oxygen species-responsive dual-targeted nanosystem promoted immunogenic cell death against breast cancer.Bioengineering & translational medicine · 2023Article
- Upconversion nanoparticle platform for efficient dendritic cell antigen delivery and simultaneous tracking.Mikrochimica acta · 2022Article
- The Role of Toll-like Receptor Agonists and Their Nanomedicines for Tumor Immunotherapy.Pharmaceutics · 2022Review
- Optically Coupled PtOEP and DPA Molecules Encapsulated into PLGA-Nanoparticles for Cancer Bioimaging.Biomedicines · 2022Article
- Advancing immune checkpoint blockade in colorectal cancer therapy with nanotechnology.Frontiers in immunology · 2022Review
- A tumor microenvironment-related mRNA-ncRNA signature for prediction early relapse and chemotherapeutic sensitivity in early-stage lung adenocarcinoma.Journal of cancer research and clinical oncology · 2021Article
- Engineering nanotheranostic strategies for liver cancer.World journal of gastrointestinal oncology · 2021Article
- Functionalized Nanoparticles Targeting Tumor-Associated Macrophages as Cancer Therapy.Pharmaceutics · 2021Review
- Combining Photodynamic Therapy with Immunostimulatory Nanoparticles Elicits Effective Anti-Tumor Immune Responses in Preclinical Murine Models.Pharmaceutics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chemoimmunotherapy is an emerging combinatorial modality for the treatment of cancers resistant to common first-line therapies, such as chemotherapy and checkpoint blockade immunotherapy. We used biodegradable nanoparticles as delivery vehicles for local, slow and sustained release of doxorubicin, two immune adjuvants and one chemokine for the treatment of resistant solid tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.